SAN MATEO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), an award-winning digital health company that improves medication adherence, patient outcomes and engagement, today announced that David Allinson has joined the Company as Chief Financial Officer, effective immediately.
“We are delighted to welcome David to our team. His extensive background in finance, corporate development and transaction management, predominantly in the medical technology sector, made him an ideal candidate for this key position in our organization,” said Arik Anderson, CEO. “I am confident in David's ability to guide and implement our financial strategy and high-growth initiatives as we progress towards becoming the global leader in medical adherence.”
Mr. Allinson brings more than 20 years of executive-level financial leadership to Adherium. Most recently, he was Chief Financial Officer of Augmedix, Inc., a technology-enabled documentation service for healthcare providers, where he was instrumental in completing several financial transactions and strengthening the company's overall financial structure. Previously, he served in executive and financial leadership roles at GE Medical Systems - Healthcare Solutions, The Self Health Network, MECON, Inc., and HCORP, Inc. Mr. Allinson began his career with Price Waterhouse, where he completed his CPA license.
“I’m delighted to join Adherium at this truly dynamic stage of its development,” said Allinson. “The Company’s platform-based approach to supporting medication adherence for patients suffering from respiratory disease, as well as delivering critical and timely data to their care-givers and healthcare providers is truly unique in the healthcare industry. I look forward to contributing my expertise to the leadership team and to advance the Company’s vision to expand into the US and drive long-term growth and value.”
Mr. Allinson holds a Bachelor of Science in Accounting from San Jose State University, San Jose, CA
About Adherium
Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with over 100,000 devices distributed globally. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of connected medical devices for respiratory medications. The devices and accompanying technology address sub-optimal medication use and strive to improve health outcomes in chronic disease. Adherium is headquartered in the U.S., and operates globally from bases in the U.S., Europe and Australasia. Learn more at adherium.com.
Inquiries
Vik Panda, Adherium
Email: vikp@adherium.com
Media
Chris Gale, Greentarget
Phone: 646.695.2883
Email: cgale@greentarget.com
Investors
Leigh Salvo, Gilmartin Group
Phone: 415.937.5404
Email: leigh@gilmartinir.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/34caf2eb-47a3-4a05-9bcd-ab8567ec5f51